Abstract:Pathological aggregation of a specific protein into insoluble aggregates is a common hallmark of various neurodegenerative diseases (NDDs). In the earlier literature, each NDD is characterized by the aggregation of one or two pathogenic proteins, which can serve as disease-specific biomarkers. The aggregation of these specific proteins is thought to be a major cause of or deleterious result in most NDDs. However, accumulating evidence shows that a pathogenic protein can interact and co-aggregate with other pathogenic proteins in different NDDs, thereby contributing to disease onset and progression synergistically. During the past years, more than one type of NDD has been found to co-exist in some individuals, which may increase the complexity and pathogenicity of these diseases. This article reviews and discusses the biochemical characteristics and molecular mechanisms underlying the co-aggregation and co-pathologies associated with TDP-43 pathology. The TDP-43 aggregates, as a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), can often be detected in other NDDs, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD) and spinocerebellar ataxia type 2 (SCA2). In many cases, TDP-43 is shown to interact and co-aggregate with multiple pathogenic proteins in vitro and in vivo. Furthermore, the co-occurrence and co-aggregation of TDP-43 with other pathogenic proteins have important consequences that may aggravate the diseases. Thus, the current viewpoint that the co-aggregation of TDP-43 with other pathogenic proteins in NDDs and their relevance to disease progression may gain insights into the patho-mechanisms and therapeutic potential of various NDDs.

Conformational Enigma of TDP-43 Misfolding in Neurodegenerative Disorders

Identification of a Hidden, Highly Aggregation-Prone Intermediate of Full-Length TDP-43 That Triggers its Misfolding and Amyloid Aggregation

Electrostatics Choreographs the Aggregation Dynamics of Full-Length TDP-43 via a Monomeric Amyloid Precursor

Co-Aggregation of TDP-43 with Other Pathogenic Proteins and Their Co-Pathologies in Neurodegenerative Diseases

Prion-like Spreading of Disease in TDP-43 Proteinopathies

Molecular Visualization of Neuronal TDP43 Pathology In Situ

TDP43 and Huntingtin Exon-1 Undergo A Conformationally Specific Interaction That Strongly Alters the Fibril Formation of Both Proteins

A computational approach to investigate TDP-43 C-terminal fragments aggregation in Amyotrophic Lateral Sclerosis

Insights into the Aggregation Mechanism of RNA Recognition Motif Domains in TDP-43: a Theoretical Exploration

A transient protein folding response targets aggregation in the early phase of TDP-43-mediated neurodegeneration

Insights into the Aggregation Mechanism of RRM Domains in TDP-43: A Molecular Dynamics Study

TDP43 aggregation at ER-exit sites impairs ER-to-Golgi transport

Cryo-EM structures of four polymorphic TDP-43 amyloid cores

Proteomics elucidating physiological and pathological functions of TDP-43

Cryo-EM observation of the amyloid key structure of polymorphic TDP-43 amyloid fibrils

Manipulating TDP43 Aggregation via RNA G-quadruplexes

An ALS-mutant TDP-43 Neurotoxic Peptide Adopts an Anti-Parallel Β-Structure and Induces TDP-43 Redistribution.

Intra-condensate demixing of TDP-43 inside stress granules generates pathological aggregates